Pfizer will manufacture remdesivir for Gilead at its facility in McPherson, Kan.
“From the beginning it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis,” Pfizer’s CEO, Albert Bourla, PhD, said in a news release. “Pfizer’s agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions.”
The agreement comes a couple days after 34 attorneys general wrote a letter urging federal health officials to boost the national supply of remdesivir.
More articles on pharmacy:
32 pharmacies ranked by customer satisfaction
Eli Lilly drug first in series to be studied as coronavirus treatment by NIH
An updated timeline on hydroxychloroquine, the controversial potential COVID-19 treatment
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
